4/24
11:33 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.
4/24
09:56 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/23
10:48 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/22
12:42 pm
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/22
12:42 pm
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/22
07:10 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/22
07:10 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/17
11:28 am
itci
Rating for ITCI
Medium
Report
Rating for ITCI
4/17
11:28 am
itci
Rating for ITCI
Medium
Report
Rating for ITCI
4/17
11:28 am
itci
Rating for ITCI
Medium
Report
Rating for ITCI
4/17
07:35 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/17
07:35 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/16
08:00 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.
4/16
07:56 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/16
07:56 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/5
08:03 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.
4/5
05:13 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/5
05:13 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/3
09:31 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
4/3
09:31 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
4/3
08:48 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
4/3
08:48 am
itci
Rating for ITCI
Low
Report
Rating for ITCI
2/23
12:15 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
2/23
12:15 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
2/23
12:15 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $101.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $101.00 price target on the stock.